Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin®)

Strahlentherapie und Onkologie

Volumn 177, Issue 12, 2001, Pages 656-661

  Groß, Markus W ^a   Altscher, Riglef ^a   Brandtner, Michael ^b   Häußer Mischlich, Harald ^c   Kiricuta, Ion C ^d   Siegmann, Alessandra D ^e   Engenhart Cabillic, Rita ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Städtisches Klinikum Wetzlar   (Germany)

^c KLINIKUM FULDA   (Germany)

^d Städtisches Klinikum Limburg   (Germany)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Glioblastoma; Quality of life; Radio chemotherapy; Topotecan; Toxicity

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; STEROID; TOPOTECAN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NAUSEA; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RADIOSENSITIVITY; SEPSIS; TREATMENT PLANNING;

EID: 0035664615     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002380     Document Type: Article

References (31)

1. Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants
2. Cerebrospinal fluid and penetration of continuous infusion topotecan in children with central nervous system tumours
3. Radiation response and survival time in patients with glioblastoma multiforme
4. Phase II evaluation of topotecan for pediatric central nervous system tumours
5. Interaction of topoisomerase I inhibitors with radiation in cis-diammine-dichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo
6. Topotecan for recurrent malignant glioma: Long times to tumour progression may indicate efficacy
7. Camptothecin overcomes MDR-1-mediated resistance in human KB carcinoma cells
8. DNA topoisomerases: Essential enzymes and lethal targets
9. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
10. Topotecan as a 21-day continuous infusion with accelerated 3d-conformal radiation therapy for patients with glioblastoma
11. Malignant glioma: Patterns of failure following individually tailored limited volume irradiation
12. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor or DNA topoisomerase I
13. The role of tumour resection in the treatment of glioblastoma multiforme in adults
14. Topoisomerase I inhibitors potentiate radiation lethality in vitro
15. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: Report of a synergistic effect between topotecan and radiation
16. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation
17. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase inhibitors
18. Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment
19. Phase II study of topotecan in patients with recurrent malignant glioma
20. Patterns of second recurrence of malignant astrocytomas
21. Camptothecin radiation sensitization: Mechanisms, schedules and timing
22. High dose radiation therapy in the treatment of malignant gliomas: Final report
23. Topoisomerase-I-inhibitor mit potentiell strahlensensibilisierender wirkung
24. Systematik der akuten und chronischen strahlenfolgen
25. The European organization for research and treatment of cancer approach to developing questionnaire modules: An update and overview
26. Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity
27. Interaction of topotecan with ionizing radiation in two human tumour cell lines
28. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
29. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. RTOG study 83-02
30. Prognostic factors in high-grade malignant glioma